Introduction: The aim of the study was to evaluate the effect of administration of therapeutic doses of ceftiofur and tulathromycin on the circulating lymphocyte subpopulations in healthy pigs. Material and Methods: The study was conducted on thirty healthy 7- to 10-week-old pigs, assigned to three groups: the TUL group, injected with tulathromycin (n = 10); the CEF group, injected with ceftiofur (n = 10); and the C group, the control with no antibiotic administration (n = 10). Blood samples were collected before, during, and after treatment with antimicrobials. Lymphocyte subpopulations circulating in the blood were determined by immunostaining and flow cytometry analyses. Results: Following administration of a therapeutic dose of tulathromycin, there were no changes in the lymphocyte subpopulations circulating in blood. In contrast, administration of ceftiofur at the recommended dose decreased the absolute number of CD3+, CD21+, CD4+CD8-, CD4-CD8+, and double positive CD4CD8 cells. Conclusion: Results from the study indicate that ceftiofur possesses the ability to modulate the immune system in healthy pigs by decreasing lymphocyte subpopulations circulating in blood.

The pharmacokinetic profile of ceftiofur sodium, a third generation cephalosporin, was studied in both Friesian and buffalo calves following a single intravenous and intramuscular administration of 2.2 mg kg-1 b.wt. in a cross over study with 15-day wash out period. After i.v administration the serum concentration-time curve of ceftiofur sodium was best fitted using two-compartments open model, with distribution half-lives (t½(()) of 0.384 and 0.176 h., elimination half-lives (t½(0)) of 5.047 and 1.607 h., mean residence time (MRT) of 6.926 and 2.072 h., volumes of distribution at steady-state (Vdss) of 0.206 and 0.134 L kg-1 and total body clearance (ClB) of 0.029 and 0.065 L kg-1 h-1 in Friesian and buffalo calves, respectively. Following intramuscular administration, the drug absorbed with half-lives of absorption (t½(ab)) of 1.010 and 0.217 h., maximum serum concentrations (Cmax) of 5.539 and 9.663 g ml-1 which attained after (tmax) of 3.147 and 0.825 h. and the drug was eliminated with half-lives (t½(el)) of 5.239 and 1.750 h. in Friesian and buffalo calves, respectively. The systemic intramuscular bioavailabilities were 89.82 and 99.7 %, while the in-vitro serum proteinbinding tendencies were 39.68 and 14.44 % in Friesian and buffalo calves, respectively

Early detection of the reproductive problems is fundamental to improve reproductive efficiency of dairy farms. Therefore, the study was performed to compare between two treatment protocols of pyometra to optimize reproductive performance of dairy cows. Based on rectal and ultrasonographic examinations, 30 cows suffered from pyometra were divided into; group1 (n=10) control group, group2 (n=10): treated with two injections of prostaglandin (PGF2α) plus systemic ceftiofur and group3 (n=10): treated with systemic ceftiofur. Ultrasonographic examination was performed before and 11 days after treatment. Blood samples were collected for analysis of progesterone (P4) and estradiol 17-ß just before and 11 days after treatment. Reproductive data was obtained regarding the1st and 2nd service conception rate (the 1st SCR and the 2nd SCR), number of services/conception (s/c) and days open. Ultrasonographic examination of the uterine horns appeared to be filled with hyperechoic granules in the lumen. However, the uterine horns at 11 days after treatment decreased in size and hyperechoic granules disappeared. No significant differences in P4 and estradiol 17- ß before and 11days after treatment. In cows received PGF2α+ ceftiofur, estradiol 17- ß was lower before treatment than 11 days after treatment. Significant improvement in the reproductive performance was recorded in treated cows with PGF2α+ceftiofur that manifested by marked increase in SCR and S/C as well as decrease in days open as compared with treated cows with ceftiofur only. It was concluded that double PGF2α injection+systemic ceftiofur is the best protocol to control pyometra that was pronounced by enhancement of reproductive performance in dairy cows.

Bovine respiratory disease (BRD) is one of the most serious diseases counted for economic loss and extensive usage of antibiotics in cattle. Ceftiofur, a third-generation cephalosporin antibiotic, has been approved for use in cattle in the United States. This study was done to investigate the clinical effect of ceftiofur on calves as well as its efficacy and safety for treating BRD. Thirty Holstein calves from a dairy farm were divided into three groups. Group I served as a health control group. Group II consisted of healthy animals while Group III comprised calves clinically diagnosed with BRD. Both groups II and III received a single subcutaneous injection of ceftiofur (2mg/kg B.W) in the ear. All groups were clinically evaluated at day 0, 7, and 14 after drug administration for illness score, body weight, body gain, feed intake, body temperature, depression score, discharges, ear and coughing score. Clinical illness score showed clear signs of BRD (elevation of body temperature and depression). Nasal and ocular discharges were recorded and ranked. Significant increases in ear and coughing score were observed in diseased calves.